CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Recruiting now · Phase 1/Phase 2
Conditions studied: Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma, Marginal Zone Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Central Nervous System Lymphoma
In brief
This is a Phase I/II, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 (IL-7/IL-15) manufactured chimeric antigen receptor (CAR)-20/19-T cells as well as the feasibility of a flexible manufacturing schema in adult patients with B cell malignancies that have failed prior therapies.
Key facts
- Study ID
- NCT04186520
- Run by
- Medical College of Wisconsin
- People needed
- 100
- Starts
- 2020-05-18
- Expected to finish
- 2029-02-28
- Last updated by the study team
- 2026-02-23
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Medical College of Wisconsin and Froedtert Hospital — Milwaukee, Wisconsin, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.